HARROW HEALTH, INC. Contracts & Agreements

Description of the Companys Securities (Filed With SEC on March 19, 2024)

Third Amendment to License and Supply Agreement dated February 6, 2024 between Harrow IP, LLC and Sintetica S.A (Filed With SEC on March 19, 2024)

Second Amendment to License and Supply Agreement, dated August 4, 2023, between Harrow IP, LLC and Sintetica S.A (Filed With SEC on November 13, 2023)

Underwriting Agreement between the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein, dated July 18, 2023 (Filed With SEC on July 21, 2023)

Loan and Security Agreement dated December 14, 2022, between the Company and B. Riley Commercial Capital, LLC (Filed With SEC on May 11, 2023)

Description of the Companys Securities (Filed With SEC on March 23, 2023)

Second Supplemental Indenture, dated as of December 20, 2022, by and between the Company and U.S. Bank Trust Company, National Association (Filed With SEC on December 20, 2022)

Common Stock Underwriting Agreement between the Company and B. Riley Securities, Inc. dated December 13, 2022 (Filed With SEC on December 16, 2022)

Notes Underwriting Agreement between the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein, dated December 15, 2022 (Filed With SEC on December 16, 2022)

Asset Purchase Agreement dated December 13, 2022, between the Company and Novartis Technology, LLC and Novartis Innovative Therapies AG (Filed With SEC on December 14, 2022)

First Amendment to Loan and Security Agreement, dated as of April 8, 2022, between the Company and Melt Pharmaceuticals, Inc (Filed With SEC on November 14, 2022)

Second Amendment to Loan and Security Agreement, dated as of September 21, 2022, between the Company and Melt Pharmaceuticals, Inc (Filed With SEC on November 14, 2022)

Mutual Termination Agreement, dated October 7, 2022 between ImprimisRx and EyePoint Pharmaceuticals, Inc (Filed With SEC on November 14, 2022)

First Amendment to Loan and Security Agreement, dated as of April 8, 2022, between the Company and Melt Pharmaceuticals, Inc (Filed With SEC on August 9, 2022)

Description of the Companys Securities (Filed With SEC on March 10, 2022)

Expansion Term Letter Agreement between Eyepoint Pharmaceuticals, Inc. and ImprimisRx, LLC dated December 6, 2021 (Filed With SEC on March 10, 2022)

Asset Purchase Agreement, dated as of December 17, 2021, by and between the Company and Novartis Technology, LLC and Novartis Ophthalmics AG (Filed With SEC on March 10, 2022)

Basic Sale and Purchase Agreement, dated as of August 18, 2021, by and between the Company and Wakamoto Pharmaceutical Co., Ltd (Filed With SEC on November 9, 2021)

License Agreement, dated as of August 18, 2021, by and between the Company and Wakamoto Pharmaceutical Co., Ltd (Filed With SEC on November 9, 2021)

Loan and Security Agreement, dated September 1, 2021, by and between the Company and Melt Pharmaceuticals, Inc (Filed With SEC on September 2, 2021)

License and Supply Agreement, dated as of July 25, 2021, by and between the Company and Sintetica, S.A (Filed With SEC on August 10, 2021)

Underwriting Agreement, dated as of June 14, 2021, by and among the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein (Filed With SEC on June 17, 2021)

Securities Purchase Agreement, dated as of May 5, 2021, by and between the Company and B. Riley Securities, Inc (Filed With SEC on May 5, 2021)

Underwriting Agreement, dated as of April 15, 2021, by and between the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein (Filed With SEC on April 20, 2021)

Indenture, dated as of April 20, 2021, by and between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on April 20, 2021)

First Supplemental Indenture, dated as of April 20, 2021, by and between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on April 20, 2021)

Underwriting Agreement, dated as of April 8, 2021, by and among Harrow Health, Inc., Eton Pharmaceuticals, Inc. and National Securities Corporation (Filed With SEC on April 8, 2021)

Description of the Companys Securities (Filed With SEC on March 8, 2021)

Consulting Agreement dated July 1, 2020 between Visionology, Inc. and Mark L. Baum (Filed With SEC on March 8, 2021)

Consulting Agreement dated July 1, 2020 between Visionology, Inc. and Andrew R. Boll (Filed With SEC on March 8, 2021)

First Amendment to Commercial Alliance Agreement between Eyepoint Pharmaceuticals, Inc. and ImprimisRx, LLC dated November 13, 2020 (Filed With SEC on March 8, 2021)

Commercial Alliance Agreement between Eyepoint Pharmaceuticals, Inc. and ImprimisRx, LLC dated August 1, 2020 (Filed With SEC on November 9, 2020)

Business Loan Agreement with Renasant Bank pursuant to the Paycheck Protection Program, dated April 27, 2020 (Filed With SEC on August 10, 2020)

Description of the Companys Securities (Filed With SEC on March 13, 2020)

Consulting Agreement dated February 13, 2020 between Stowe Pharmaceuticals, Inc. and Mark L. Baum (Filed With SEC on March 13, 2020)

Consulting Agreement dated February 13, 2020 between Stowe Pharmaceuticals, Inc. and Andrew R. Boll (Filed With SEC on March 13, 2020)

Consulting Agreement dated February 13, 2020 between Stowe Pharmaceuticals, Inc. and John P. Saharek (Filed With SEC on March 13, 2020)

Asset Purchase Agreement, dated July 26, 2019, by and between Park Compounding, Inc. and Noice Rx, LLC (Filed With SEC on November 13, 2019)

Loan Agreement, dated July 26, 2019, by and between Park Compounding, Inc. and Noice Rx, LLC (Filed With SEC on November 13, 2019)

License Agreement, dated July 28, 2019, among Mayfield Pharmaceuticals, Inc., TGV-Health, LLC and TGV-Gyneconix, LLC (Filed With SEC on November 13, 2019)

License Agreement, dated July 29, 2019, among Stowe Pharmaceuticals, Inc., TGV-Health, LLC and TGV-Ophthalnix, LLC (Filed With SEC on November 13, 2019)

Consulting Agreement dated June 3, 2019 between Mayfield Pharmaceuticals, Inc. and Andrew R. Boll (Filed With SEC on August 14, 2019)

Consulting Agreement dated June 3, 2019 between Mayfield Pharmaceuticals, Inc. and Mark L. Baum (Filed With SEC on August 14, 2019)

Consulting Agreement dated June 3, 2019 between Mayfield Pharmaceuticals, Inc. and John P. Saharek (Filed With SEC on August 14, 2019)

Joinder and Amendment to Loan and Security Agreement, dated May 24, 2019, by and between Harrow Health, Inc., each of its wholly-owned subsidiaries and SWK Funding LLC (Filed With SEC on May 29, 2019)

Asset Purchase Agreement dated February 1, 2019 between Harrow Health, Inc. and Mayfield Pharmaceuticals, Inc (Filed With SEC on May 9, 2019)

Asset Purchase Agreement dated February 1, 2019 between Harrow Health, Inc. and Elle Pharmaceuticals, Inc (Filed With SEC on May 9, 2019)

Asset Purchase Agreement dated December 11, 2018 between Imprimis Pharmaceuticals, Inc. and Melt Pharmaceuticals, Inc (Filed With SEC on February 5, 2019)

Consulting Agreement dated May 1, 2018 between Melt Pharmaceuticals, Inc. and Mark L. Baum (Filed With SEC on November 13, 2018)

Consulting Agreement dated May 1, 2018 between Melt Pharmaceuticals, Inc. and Andrew R. Boll (Filed With SEC on November 13, 2018)

Consulting Agreement dated May 1, 2018 between Melt Pharmaceuticals, Inc. and John P. Saharek (Filed With SEC on November 13, 2018)

Amended and Restated License Agreement dated April 10, 2018 between Imprimis Pharmaceuticals, Inc. and Richard L. Lindstrom, M.D (Filed With SEC on August 6, 2018)

Consulting Agreement dated March 1, 2018 between Surface Pharmaceuticals, Inc. and Richard L. Lindstrom, M.D (Filed With SEC on August 6, 2018)

Asset Purchase and License Agreement dated September 28, 2017 between Imprimis Pharmaceuticals, Inc. and Surface Pharmaceuticals, Inc (Filed With SEC on May 15, 2018)

Amend and Restated Asset Purchase and License Agreement dated April 10, 2018 between Imprimis Pharmaceuticals, Inc. and Surface Pharmaceuticals, Inc (Filed With SEC on May 15, 2018)

Consulting Agreement dated October 27, 2017 between Surface Pharmaceuticals, Inc. and Mark L. Baum (Filed With SEC on March 8, 2018)

Consulting Agreement dated October 27, 2017 between Surface Pharmaceuticals, Inc. and Andrew R. Boll (Filed With SEC on March 8, 2018)

Consulting Agreement dated October 27, 2017 between Surface Pharmaceuticals, Inc. and John P. Saharek (Filed With SEC on March 8, 2018)

Eton Letter dated September 20, 2017 (Filed With SEC on September 21, 2017)

ASSETPURCHASE AGREEMENT (Filed With SEC on August 10, 2017)

ConsultingAgreement (Filed With SEC on August 10, 2017)

LOANAND SECURITY AGREEMENT (Filed With SEC on July 20, 2017)

ASSETPURCHASE AND LICENSE AGREEMENT (Filed With SEC on June 20, 2017)

AMENDEDAND RESTATED CERTIFICATEOF INCORPORATION OF ETONPHARMACEUTICALS, INC. ADelaware Corporation (Pursuantto Sections 242 and 245 of the GeneralCorporation Law of the State of... (Filed With SEC on June 20, 2017)

MANAGEMENTSERVICES AGREEMENT (Filed With SEC on June 20, 2017)

IMPRIMISPHARMACEUTICALS, INC. 2017INCENTIVE STOCK AND AWARDS PLAN INCENTIVESTOCK OPTION AGREEMENT (Filed With SEC on June 16, 2017)

IMPRIMISPHARMACEUTICALS, INC. 2017INCENTIVE STOCK AND AWARD PLAN FORMOF NONQUALIFIEDSTOCK OPTION AGREEMENT (Filed With SEC on June 16, 2017)

IMPRIMISPHARMACEUTICALS, INC. 2017INCENTIVE STOCK AND AWARDS PLAN NOTICEOF RESTRICTED STOCK AWARD (Filed With SEC on June 16, 2017)

IMPRIMISPHARMACEUTICALS, INC. 2017INCENTIVE STOCK AND AWARDS PLAN NOTICEOF Restricted Stock Unit AWARD (Filed With SEC on June 16, 2017)

STRATEGICSALES & MARKETING AGREEMENT (Filed With SEC on May 2, 2017)

STRATEGICSALES & MARKETING AGREEMENT (Filed With SEC on April 17, 2017)

LICENSEAGREEMENT (Filed With SEC on April 6, 2017)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on March 22, 2017)

STOCKPURCHASE AGREEMENT (Filed With SEC on February 17, 2017)

THIRDAMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on December 29, 2016)

EXCHANGEAND DISCHARGE AGREEMENT (Filed With SEC on December 29, 2016)

AMENDMENTNO. 2 TO WARRANT TO PURCHASE STOCK (Filed With SEC on December 29, 2016)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on December 23, 2016)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on December 23, 2016)

IMPRIMISPHARMACEUTICALS, INC. COMMONSTOCK PURCHASE WARRANT (Filed With SEC on December 23, 2016)

COMMERCIAL LEASE AGREEMENT (Filed With SEC on August 11, 2016)

IMPRIMISPHARMACEUTICALS, INC. EMPLOYMENTAGREEMENT (Filed With SEC on April 26, 2016)

IMPRIMISPHARMACEUTICALS, INC. AMENDED AND RESTATED 2007 INCENTIVE STOCK AND AWARDS PLAN PERFORMANCESTOCK UNITS AGREEMENT (Filed With SEC on April 26, 2016)

[REMAINDEROF PAGE LEFT INTENTIONALLY BLANK] (Filed With SEC on April 26, 2016)

IMPRIMISPHARMACEUTICALS, INC. EMPLOYMENTAGREEMENT (Filed With SEC on April 26, 2016)

IMPRIMISPHARMACEUTICALS, INC. AMENDED AND RESTATED 2007 INCENTIVE STOCK AND AWARDS PLAN PERFORMANCESTOCK UNITS AGREEMENT (Filed With SEC on April 26, 2016)

[REMAINDEROF PAGE LEFT INTENTIONALLY BLANK] (Filed With SEC on April 26, 2016)

IMPRIMISPHARMACEUTICALS, INC. EMPLOYMENTAGREEMENT (Filed With SEC on April 26, 2016)

[REMAINDEROF PAGE LEFT INTENTIONALLY BLANK] (Filed With SEC on April 26, 2016)

COMMISSIONAGREEMENT (Filed With SEC on March 23, 2016)

IMPRIMISPHARMACEUTICALS, inc. 2,900,000 SHARESOF COMMON STOCK UNDERWRITINGAGREEMENT (Filed With SEC on March 11, 2016)

IMPRIMISPHARMACEUTICALS, INC. 8.00%Convertible Senior Secured Note (Filed With SEC on January 25, 2016)

Imprimis Pharmaceuticals, Inc. 8.00% Convertible Senior Secured Note Note Purchase Agreement (Filed With SEC on January 25, 2016)

SECONDAMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on January 25, 2016)

AMENDMENTTO WARRANT TO PURCHASE STOCK (Filed With SEC on January 25, 2016)

ImprimisPharmaceuticals, Inc. Sharesof Common Stock (parvalue $0.001 per share) ControlledEquity OfferingSM SalesAgreement (Filed With SEC on November 27, 2015)

ASSETPURCHASE AGREEMENT (Filed With SEC on November 12, 2015)

STOCKPURCHASE AGREEMENT byand among IMPRIMISPHARMACEUTICALS, INC., JONATHANNGUYEN, JULIETRINH and JTPHARMACY, INC. (D/B/ACENTRAL ALLEN PHARMACY) Datedas of July 10, 2015 (Filed With SEC on August 12, 2015)

LICENSEAGREEMENT (Filed With SEC on August 12, 2015)

FIRSTAMENDMENT TO AMENDEDAND RESTATED EMPLOYMENTAGREEMENT (Filed With SEC on August 5, 2015)

IMPRIMISPHARMACEUTICALS, INC. NONQUALIFIEDSTOCK OPTION AGREEMENT (Filed With SEC on August 5, 2015)

[ImprimisLetterhead] (Filed With SEC on August 5, 2015)

LOANAND SECURITY AGREEMENT (Filed With SEC on May 12, 2015)

WARRANTTO PURCHASE STOCK (Filed With SEC on May 12, 2015)

IMPRIMISPHARMACEUTICALS, INC. AMENDEDAND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on February 2, 2015)

IMPRIMIS PHARMACEUTICALS, INC. AMENDED AND RESTATED 2007 INCENTIVESTOCK AND AWARDS PLAN PERFORMANCE STOCK UNITS AGREEMENT (Filed With SEC on February 2, 2015)

IMPRIMISPHARMACEUTICALS, INC. EMPLOYMENTAGREEMENT (Filed With SEC on February 2, 2015)

STOCKPURCHASE AGREEMENT byand among IMPRIMISPHARMACEUTICALS, INC., DENNISSAADEH, TINASULIC-SAADEH, SOUTHCOAST SPECIALTY COMPOUNDING (D/B/APARK COMPOUNDING) and... (Filed With SEC on December 2, 2014)

LICENSEAGREEMENT (Filed With SEC on October 29, 2014)

CONFIDENTIALTREATMENT REQUESTED. OMITTED PORTIONS ARE MARKED WITH [***] AND HAVE BEEN FILED SEPARATELY WITH THE SEC. (Filed With SEC on March 28, 2014)

AMENDMENT TO ASSET PURCHASE AGREEMENT (Filed With SEC on March 28, 2014)

MEMBERSHIPINTEREST PURCHASE AGREEMENT among JOHNSCOTT KAROLCHYK and BERNARD COVALESKY and IMPRIMISPHARMACEUTICALS, INC. datedas of February10, 2014 (Filed With SEC on February 11, 2014)

CONFIDENTIAL TREATMENT REQUESTED.OMITTED PORTIONS ARE MARKED WITH [***] AND HAVE BEEN FILED SEPARATELY WITH THE SEC. ASSETPURCHASE AGREEMENT (Filed With SEC on November 6, 2013)

AMENDMENT TO ASSET PURCHASEAGREEMENT (Filed With SEC on November 6, 2013)

AmendmentNo. 1 to the Imprimis Pharmaceuticals, Inc. Amendedand Restated 2007 Incentive Stock and Awards Plan (Filed With SEC on November 6, 2013)

IMPRIMIS PHARMACEUTICALS, INC. PERFORMANCE STOCK UNITS AGREEMENT (Filed With SEC on August 14, 2013)

CONFIDENTIAL TREATMENT REQUESTED. OMITTED PORTIONS ARE MARKED WITH [***] AND HAVE BEEN FILED SEPARATELY WITH THE SEC. (Filed With SEC on August 14, 2013)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on May 8, 2013)

IMPRIMIS PHARMACEUTICALS, INC. AMENDED AND RESTATED 2007 INCENTIVE STOCK AND AWARDS PLAN (as amended and restated on May 2, 2013) (Filed With SEC on May 8, 2013)

IMPRIMIS PHARMACEUTICALS, INC. AMENDED AND RESTATED 2007 INCENTIVE STOCK AND AWARDS PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD Grantees Name and Address: (Filed With SEC on May 8, 2013)

Strategic Alliance Agreement, dated February 18, 2013, by and between the Company and Professional Compounding Centers of America, Inc (Filed With SEC on February 21, 2013)

Underwriting Agreement, dated February 7, 2013, by and between the Company and MDB Capital Group, LLC (Filed With SEC on February 8, 2013)

IMPRIMIS PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT (Filed With SEC on October 26, 2012)

IMPRIMIS PHARMACEUTICALS, INC. UNDERWRITERS WARRANT (Filed With SEC on October 26, 2012)

License Agreement, dated as of August 30, 2012, by and between Imprimis Pharmaceuticals, Inc. and Professional Compounding Centers of America, Inc (Filed With SEC on August 31, 2012)

Stock Purchase Agreement, dated as of August 30, 2012, by and between Imprimis Pharmaceuticals, Inc. and Professional Compounding Centers of America, Inc (Filed With SEC on August 31, 2012)

AMENDMENT NO. 3 TO THE IMPRIMIS PHARMACEUTICALS, INC. 2007 INCENTIVE STOCK AND AWARDS PLAN (Filed With SEC on July 25, 2012)

FIRST AMENDED SECURITIES PURCHASE AGREEMENT (Filed With SEC on July 25, 2012)

IMPRIMIS PHARMACEUTICALS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on July 25, 2012)

AMENDMENT TO ADVISORY AGREEMENT (Filed With SEC on July 25, 2012)

TERMINATION AGREEMENT (Filed With SEC on July 25, 2012)

CONVERSION AGREEMENT (Filed With SEC on July 25, 2012)

IMPRIMIS PHARMACEUTICALS, INC. NOTICE OF STAND-ALONE RESTRICTED STOCK UNIT AWARD (Filed With SEC on July 25, 2012)

IMPRIMIS PHARMACEUTICALS, INC. NOTICE OF STAND-ALONE RESTRICTED STOCK UNIT AWARD Grantees Name and Address:Robert J. Kammer (Filed With SEC on July 25, 2012)

Waiver and Settlement Agreement, effective as of January 25, 2012, by and between Imprimis Pharmaceuticals, Inc. and Alexej Ladonnikov (Filed With SEC on May 10, 2012)

Waiver and Settlement Agreement, effective as of January 25, 2012, by and between Imprimis Pharmaceuticals, Inc. and DermaStar International, LLC (Filed With SEC on May 10, 2012)

Senior Advisory Agreement, dated as of January 17, 2012, by and between Imprimis Pharmaceuticals, Inc. and Paul Finnegan, M.D (Filed With SEC on May 10, 2012)

Employment Agreement, dated as of January 25, 2012, by and between Imprimis Pharmaceuticals, Inc. and Dr. Balbir Brar, D.V.M., Ph.D (Filed With SEC on May 10, 2012)

Employment Agreement, dated as of February 1, 2012, by and between Imprimis Pharmaceuticals, Inc. and Andrew R. Boll (Filed With SEC on May 10, 2012)

Employment Agreement, dated as of February 15, 2012, by and between Imprimis Pharmaceuticals, Inc. and Joachim Schupp, M.D (Filed With SEC on May 10, 2012)

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT (Filed With SEC on April 27, 2012)

Exhibit 10.2 (Filed With SEC on April 27, 2012)

Exhibit 10.3 PROMISSORY NOTE CONVERSION AGREEMENT (Filed With SEC on April 27, 2012)

Exhibit 10.4 Advisory Agreement (Filed With SEC on April 27, 2012)

Exhibit 10.5 IMPRIMIS PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT (Filed With SEC on April 27, 2012)

Exhibit 10.1 (Filed With SEC on December 20, 2011)

Exhibit 10.2 SECURITY AGREEMENT (Filed With SEC on December 20, 2011)

Exhibit 10.3 INTELLECTUAL PROPERTY SECURITY AGREEMENT (Filed With SEC on December 20, 2011)

Exhibit 10.4 SECURITIES PURCHASE AGREEMENT (Filed With SEC on December 20, 2011)

Exhibit 10.5 MUTUAL GENERAL RELEASE AGREEMENT (Filed With SEC on December 20, 2011)

ASSET PURCHASE AGREEMENT DATED AS OF JUNE 26, 2011 BY AND AMONG TRANSDEL PHARMACEUTICALS, INC., AS SELLER AND CARDIUM HEALTHCARE, INC., AS PURCHASER AND CARDIUM THERAPEUTICS INC. (Filed With SEC on June 27, 2011)

Financial Statements (Filed With SEC on November 8, 2010)

TRANSDEL PHARMACEUTICALS, INC. (Filed With SEC on April 8, 2010)

SENIOR CONVERTIBLE PROMISSORY NOTE $ ,2010 (NoteDate) San Diego, California (Filed With SEC on April 8, 2010)

DESCRIPTION OF BUSINESS (Filed With SEC on March 31, 2010)

Proposal for Clinical Trial Services to Support Transdel PharmaceuticalsInc.s Ketotransdel for the Treatment of Mild to Moderate Acute Soft Tissue Injury Prepared for: 4225... (Filed With SEC on August 11, 2008)

SUBSCRIPTION AGREEMENT (Filed With SEC on May 15, 2008)

WARRANT (Filed With SEC on May 15, 2008)

AGREEMENT OF MERGER AND PLAN OF REORGANIZATION BY AND AMONG TRANSDEL PHARMACEUTICALS, INC. TRANS-PHARMA ACQUISITION CORP. and TRANS-PHARMA CORPORATION Dated as of September 17,... (Filed With SEC on September 21, 2007)

CERTIFICATE OF MERGER OF TRANS-PHARMA ACQUISITION CORP. (a Delaware corporation) WITH AND INTO TRANS-PHARMA CORPORATION (a Nevada corporation) (Pursuant to Section 252(c) of the... (Filed With SEC on September 21, 2007)

SUBSCRIPTION AGREEMENT (Filed With SEC on September 21, 2007)

WARRANT (Filed With SEC on September 21, 2007)

TRANSDEL PHARMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT ______________, 2007 (Filed With SEC on September 21, 2007)

LOCK-UP AGREEMENT (Filed With SEC on September 21, 2007)

Trans-Pharma Corporation 4225 Executive Square, Suite 460 La Jolla, CA 92037 September 17, 2007 (Filed With SEC on September 21, 2007)

Trans-Pharma Corporation 4225 Executive Square, Suite 460 La Jolla, CA 92037 (Filed With SEC on September 21, 2007)

INDEMNITY AGREEMENT (Filed With SEC on September 21, 2007)

ASSIGNMENT OF EMPLOYMENT AGREEMENT (Filed With SEC on September 21, 2007)

EMPLOYMENT AGREEMENT (Filed With SEC on September 21, 2007)

TRANSDEL PHARMACEUTICALS, INC. 2007 INCENTIVE STOCK AND AWARDS PLAN (Filed With SEC on September 21, 2007)

TRANSDEL PHARMACEUTICALS, INC. 2007 INCENTIVE STOCK AND AWARDS PLAN FORM OF INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on September 21, 2007)

TRANSDEL PHARMACEUTICALS, INC. 2007 INCENTIVE STOCK AND AWARD PLAN FORM OF NONQUALIFIED STOCK OPTION AGREEMENT (Filed With SEC on September 21, 2007)

Category

Industry

Companies

Contracts

HARROW HEALTH, INC. Contracts & Agreements